Abstract: An electrostatic precipitator is provided. The electrostatic precipitator includes an electrode part including a high voltage electrode with voltage applied thereto and a ground electrode coiled in a circumferential direction along with the high voltage electrode while being spaced apart from the high voltage electrode, and a plurality of turning flow paths inclined with respect to an axial direction of the electrode part between the high voltage electrode and the ground electrode.

Abstract: An electrostatic precipitator is provided. The electrostatic precipitator includes an electrode part including a high voltage electrode with voltage applied thereto and a ground electrode coiled in a circumferential direction along with the high voltage electrode while being spaced apart from the high voltage electrode, and a plurality of turning flow paths inclined with respect to an axial direction of the electrode part between the high voltage electrode and the ground electrode.

Abstract: The present invention provides a cell line which can be substituted for ? cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.

Abstract: The present invention provides a cell line which can be substituted for ? cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.

Abstract: The present invention relates a composition for preventing cold comprising vitamin C and ginkgetin, a use of the composition for preparing a medicine To prevent cold, a method for preventing cold by using the composition, and method for preparing cold prophylactic. The composition of the present invention has excellent inhibition effect of cold viruses such as influenza viruses, coronaviruses, rhinoviruses an adenoviruses, can remarkably increase immunity, and may be used as health care products for preventing cold or cold medicine without cytotoxicity.

Abstract: The present invention provides a cell line which can be substituted for ? cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.

Abstract: The invention provides a T2D mouse comprising a progeny from mating a C57BL/6 mouse and a DBA/2 mouse and exhibiting a blood glucose level of at least about 200 mg/dl, wherein the mouse is a non-human mammalian model predictive of human type 2 diabetes. The T2D mouse also can exhibit impairment of glucose tolerance, normal or increased insulin production, impaired adipocyte or muscle glucose transport or decreased expression of at least one polypeptide involved in insulin action. Further provided is a method of producing a non-human mammal predictive of type 2 diabetes. The method includes mating a C57BL/6 mouse with a DBA/2 mouse, and backing crossing offspring of the mating with a parental DBA/2 mouse to produce a progeny exhibiting a blood glucose level of at least about 200 mg/dl that is predictive of human type 2 diabetes. A method of screening for a therapeutic agent for use in treating type 2 diabetes also is provided.

Abstract: According to the invention, there is provided a novel 3,4-dihydroxyhydrocinnamic acid derivative, designated DHH105, having blood glucose lowering effects in vivo as a result of the enhancement of glucose transport mediated by the increase of insulin receptor signaling. This invention thus relates to a 3,4-dihydroxyhydrocinnamic acid derivative useful as an anti-diabetic agent, represented by the following formula I: or pharmaceutically acceptable salts thereof, to a method for preparing the compound, and to a composition for treating diabetes comprising the same as an active ingredient.

Abstract: The invention provides an isolated tissue specific glucose responsive promoter having a polymerase binding domain 3? to at least one tripartite transcription factor binding cis element having a hepatocyte nuclear factor-1 (HNF-1) element, a CAAT/enhancer binding protein (C/EBP) response element and a glucose-response element (GRE). The promoter can include a second or third tripartite transcription factor binding cis element. A host cell including the tissue specific glucose responsive promoter of the invention also are provided. Further provided is a method of treating or preventing diabetes.

Abstract: The invention provides a vector having a nucleic acid operably linking a promoter, an intron, a secretory leader sequence encoding nucleic acid, a human betacellulin (BTC) encoding nucleic acid, or functional fragment thereof, and a polyadenylation signal sequence, wherein expression of BTC produces a secreted, mature BTC. Also provided is a vector having a nucleic acid operably linking a cytomegalovirus (CMV) promoter and enhancer region, a ?-globin chimeric intron, an albumin leader sequence encoding nucleic acid, a human betacellulin (BTC) encoding nucleic acid, or a functional fragment thereof, and an SV40 polyadenylation signal sequence, wherein expression of BTC produces a secreted, mature BTC. A host cell containing the vectors of the invention are also provided. A method of treating or preventing diabetes is further provided.

Abstract: According to the invention, there is provided a novel 3,4-dihydroxyhydrocinnamic acid derivative, designated DHH105, having blood glucose lowering effects in vivo as a result of the enhancement of glucose transport mediated by the increase of insulin receptor signaling. This invention thus relates to a 3,4-dihydroxyhydrocinnamic acid derivative useful as an anti-diabetic agent, represented by the following formula I: or pharmaceutically acceptable salts thereof, to a method for preparing the compound, and to a composition for treating diabetes comprising the same as an active ingredient.

Abstract: The invention provides a method of treating a T cell mediated disease. The method includes administering an effective amount of hCG to an asymptomatic subject over a period of time sufficient to restore persistent immune balance between regulatory and effector T cells, wherein restoring the persistent immune balance results in a reduction in the severity of the T cell mediated disease. The invention also provides a method of preventing T cell mediated disease in a pre-diseased subject. The method includes administering an effective amount of hCG to a subject at risk of developing a T cell mediated disease for sufficient duration to confer persistent immune balance between regulatory and effector T cells functions. Also provided is a pharmaceutical composition having an effective amount of substantially purified hCG in a pharmaceutically acceptable medium and a formulations thereof suitable for administration to a subject.

Abstract: A vaccine including recombinant vaccinia virus (ATCC VR-1354) having an inserted gene for coding glutamic acid decarboxylase is used for preventing type 1 diabetes mellitus. The glutamic acid decarboxylase expressed from the recombinant virus suppresses or tolerizes the autoreactive T cell, and induces immunological tolerance, thus effectively prevents or delays the development of type 1 diabetes mellitus.

Abstract: The present invention provides a cell line which can be substituted for &bgr; cells in human mature pancreatic islets and express insulin in a glucose-concentration dependent manner, and enables the easy obtainment of the number of cells which meets the demand. The present invention also provides a therapeutical cell preparation for treating diabetes. The cell lines of the present invention can be obtained by integrating both a nucleotide sequence encoding tamoxifen-induced Cre recombinase and a nucleotide sequence encoding insulin regulated by glucose-sensitive promoter into the chromosome in a human immortalized hepatic cell line FERM BP-7498 containing the TERT gene inserted in between a pair of LoxP sequences.

Abstract: The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

Abstract: The subject matter of the invention is directed to a single-chain insulin analog that is used to treat diabetes by gene therapy methods.

Abstract: The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

Abstract: The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

Abstract: The present invention relates to gene and peptide sequences of a diabetes-specific endogenous retrovirus which is derived from type 1 diabetes patients. In particular, the present invention relates to a whole genome of the diabetes-specific variant of endogenous retrovirus (ERV-9) purified from pancreatic tissues of type 1 diabetes (insulin-dependent diabetes mellitus [IDDM]) patients and its genes and peptide and their sequences, which can be used as a diagnosing reagent for type 1 diabetes and as an immunogen. The diabetes-specific retrovirus expressed exclusively in pancreatic beta cells was purified from deceased type 1 diabetes patients. Subsequently, the retroviral gene sequences were determined, and by analyzing the amino acid sequence of the peptide deduced from the gene, 21 domains of the peptide having hydrophilicity and immuno-dominancy were identified.

Abstract: Portulaca oleracea has been used throughout history for many different medicinal purposes. This invention is directed to the novel use of P. oleracea for the treatment of cancer. More specifically it is disclosed that P. oleracea has a specific and distinct effect on the inhibition and/or suppression of gastric tumor cell growth in vitro and in vivo. An aqueous extract of P. oleracea showed a tumoricidal activity against KATO III (human gastric carcinoma cell line) and COLO 320 HSR cells (human colon adenoma cell line) in a dose-dependent and time-dependent manner, but not against the non-tumorous cell lines, L929 (murine lung connective tissue) and W138 (human lung diploid cell) cells. Subcutaneous injection of six week old CD1 nude mice with COLO 320 HSR cells and subsequently Portulaca oleracea extract showed a clear inhibition of tumor growth as compared to the control nude mice which received only COLO 320 HSR cells.